Docetaxel for advanced prostate cancer: how early to start?
Publication
, Journal Article
Armstrong, AJ
Published in: Lancet Oncol
July 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
July 2015
Volume
16
Issue
7
Start / End Page
741 / 742
Location
England
Related Subject Headings
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Male
- Humans
- Antineoplastic Combined Chemotherapy Protocols
- Androgen Antagonists
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J. (2015). Docetaxel for advanced prostate cancer: how early to start? Lancet Oncol, 16(7), 741–742. https://doi.org/10.1016/S1470-2045(15)00012-1
Armstrong, Andrew J. “Docetaxel for advanced prostate cancer: how early to start?” Lancet Oncol 16, no. 7 (July 2015): 741–42. https://doi.org/10.1016/S1470-2045(15)00012-1.
Armstrong AJ. Docetaxel for advanced prostate cancer: how early to start? Lancet Oncol. 2015 Jul;16(7):741–2.
Armstrong, Andrew J. “Docetaxel for advanced prostate cancer: how early to start?” Lancet Oncol, vol. 16, no. 7, July 2015, pp. 741–42. Pubmed, doi:10.1016/S1470-2045(15)00012-1.
Armstrong AJ. Docetaxel for advanced prostate cancer: how early to start? Lancet Oncol. 2015 Jul;16(7):741–742.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
July 2015
Volume
16
Issue
7
Start / End Page
741 / 742
Location
England
Related Subject Headings
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Male
- Humans
- Antineoplastic Combined Chemotherapy Protocols
- Androgen Antagonists
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis